UK markets closed
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • FTSE 250

    22,324.19
    -210.95 (-0.94%)
     
  • AIM

    1,229.80
    -11.57 (-0.93%)
     
  • GBP/EUR

    1.1636
    -0.0053 (-0.46%)
     
  • GBP/USD

    1.3809
    -0.0115 (-0.83%)
     
  • BTC-GBP

    26,062.88
    -586.25 (-2.20%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • DOW

    33,290.08
    -533.37 (-1.58%)
     
  • CRUDE OIL

    71.50
    +0.46 (+0.65%)
     
  • GOLD FUTURES

    1,763.90
    -10.90 (-0.61%)
     
  • NIKKEI 225

    28,964.08
    -54.25 (-0.19%)
     
  • HANG SENG

    28,801.27
    +242.68 (+0.85%)
     
  • DAX

    15,448.04
    -279.63 (-1.78%)
     
  • CAC 40

    6,569.16
    -97.10 (-1.46%)
     

Portfolio Update

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

The Board notes that on 3 June 2021 Arecor Therapeutics plc ("Arecor"), one of Oxford Technology 4 VCT Plc’s (“OT4”) investee companies, floated on AIM raising £20m via a placing at 226p per Arecor share. The flotation was a success and the Arecor bid price at close had risen to 238p per Arecor share.

The most recently published unaudited net asset value (NAV) for OT4 at 30 November 2020 was 28.8p per share.

Compared to this last published OT4 NAV, the impact of the Arecor flotation in isolation is an increase in the OT4 NAV of £673k, or 5.8p per OT4 share.

Further detail – including an updated OT4 NAV as at 28 February 2021 and 31 May 2021 – will be available in the annual report which is expected to be released towards the end of this month.

For further information contact:

Oxford Technology Management

Lucius Cary

01865 784466



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting